Evidence map›Paper›PMID 42231577›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.

Ira Phadke, Divya Nambiar, George Diehl, Joon-Yong Chung, Hima Makala, Woonghee Lee, Kwamena E Baidoo, Constanza Rodriguez, Reona Okada, Zoe Schmiechen and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ira PhadkePediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Divya NambiarMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
George DiehlDepartment of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA; Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Joon-Yong ChungMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hima MakalaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Woonghee LeeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kwamena E BaidooMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Constanza RodriguezPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Reona OkadaPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Zoe SchmiechenPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
James P MaiaranaPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jangsuk OhPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Julia Sheehan-KlenkMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Robert EdingerDepartment of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA.
Jiangfeng ShiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Falguni BasuliMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
John BuckleyPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mitchell HoLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Rolf SwensonMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jessie N NedrowDepartment of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA; Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Ravi B PatelDepartment of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA; Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Biomedical Engineering, University of Pittsburgh, Pittsburgh, PA, USA.
Freddy E EscorciaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: freddy.escorcia@gmail.com.
Rosa NguyenPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: hongharosa.nguyen@nih.gov.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Engineering HCC-selective PET agentZIABC011800 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ESCORCIA, FREDDY · 2018 to 2025
$10.6M
Development of new therapies for neuroblastomaZIABC012066 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NGUYEN, HONG HA ROSA · 2022 to 2025
$5.6M
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapyR01CA275766 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Ravi Bhasker Patel · 2023 to 2026
$2.4M
Intramural NIH HHS ZIA BC011800Intramural NIH HHS ZIA BC012066NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA275766
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) efficacy depends on the presence of surface antigen. While antigen levels in leukemias can be measured in the blood or bone marrow, expression in solid tumors is often inferred from archival tissues or remains undetermined. Neuroblastoma (NB) is an aggressive pediatric solid tumor for which we have co-developed a CAR targeting glypican 2 (GPC2). Here, we developed a radiotheranostic platform comprising an antibody-based positron emission tomography (immunoPET) agent, [

Indexed as

GlypicansImmunotherapy, AdoptiveNeuroblastomaReceptors, Chimeric AntigenActiniumAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansMicePositron-Emission TomographyRadioisotopesXenograft Model Antitumor AssaysZirconiumActiniumGlypicansRadioisotopesReceptors, Chimeric AntigenZirconiumactinium-225CAR T cellsimmunotherapyneuroblastomaradiopharmaceutical therapyradiotheranosticszirconium-89

Identifiers

PMID42231577
PMCPMC13436103

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.